Latest Information Update: 15 Jul 1998
At a glance
- Originator Phytopharm
- Class Antiasthmatics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 15 Jul 1998 Discontinued-II for Asthma in United Kingdom (PO)
- 27 Feb 1998 Phase-II clinical trials for Asthma in United Kingdom (PO)
- 26 Nov 1996 Preclinical development for Asthma in United Kingdom (PO)